SPYRE THERAPEUTICS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
SPYRE THERAPEUTICS, INC. (SYRE) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $52.79 million as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2021-11-04
- 2021-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $52.79M.
- 2021-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $52.75M.
- 2020-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $110.08M.
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $29.99M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2021-09-30 | $52.79M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $52.75M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $110.08M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $29.99M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $22.81M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $13.02M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |